Marksans Pharma has posted satisfactory financial performance during the third quarter ended December 2014 and its consolidated net profit moved up by 23.3 per cent to Rs.27.72 crore from Rs.22.48 crore in the corresponding period of last year. It net sales also increased by 27.9 per cent to Rs.213.29 crore from Rs.155.78 crore. Its EBDITA went up by 47.7 per cent to Rs.52.46 crore from Rs.35.51 crore. EPS improved to Rs.0.74 from Rs.0.60 in the last period.
For the nine months ended December 2014, Marksans' consolidated net sales have taken quantum jump of 32.9 per cent and touched to Rs.626 crore from Rs.471 crore. Its consolidated net profit increased by 37.7 per cent to Rs.84.35 crore from Rs.61.28 crore. With strong growth in profits, its EPS moved up to Rs.2.23 from Rs.1.63 in the last period. The company's sales of formulations in Europe increased by over 33 per cent to Rs.401 crore from Rs.301 crore and that in US moved up 81.3 per cent to Rs.120 crore from Rs.66 crore. Similarly, its sales in Australia and New Zealand increased marginally by one per cent to Rs.67 crore. RoW sales declined by 4.1 per cent to Rs.38.65 crore from Rs.40.28 crore.
The company product portfolio spreads over major therapeutic segments of CVS, CNS, anti-diabetic, pain management, gastroenterologicals and anti-allergies.